Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.
Off-label uses include:
1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.
1160.20.10015, Baltimore, Maryland, United States
1160.20.45010, Aalborg, Denmark
1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark
Research Site, Uppsala, Sweden
Research Site, Uppsala, Sweden
St. John's Hospital / Pacific Heart, Santa Monica, California, United States
Emory University, Atlanta, Georgia, United States
Cardiology Associates of N. Mississippi, Tupelo, Mississippi, United States
1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka, Japan
1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan
PPD Development, LP, Austin, Texas, United States
Diamond Health Care Centre, Vancouver, British Columbia, Canada
Univeristy of Alberta, Edmonton, Alberta, Canada
1245.18.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.